Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Terminated 1Recruiting 1Completed 1

Sponsor Class

OTHER 9NETWORK 4INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 13Thoracic 10Gastrointestinal 7Dermatologic 6CNS 6Breast 6Other hematologic neoplasm 4Lymphoid 4Plasma cell 3Head & Neck 2Sarcoma 1Other neoplasm 1Other 1Myeloid 1Endocrine 1

Conditions

Multiple Myeloma 1112Recurrence 195Neoplasms 89Lymphoma 89Neoplasms, Plasma Cell 88Lymphoma, Non-Hodgkin 86Leukemia, Myeloid, Acute 53Hematologic Neoplasms 51Leukemia, Lymphocytic, Chronic, B-Cell 44Leukemia 37Myelodysplastic Syndromes 33Lymphoma, Large B-Cell, Diffuse 31Hodgkin Disease 31Immunoglobulin Light-chain Amyloidosis 30Breast Neoplasms 30Precursor Cell Lymphoblastic Leukemia-Lymphoma 26Hematologic Diseases 25Prostatic Neoplasms 19Paraproteinemias 19Lymphoma, B-Cell 19Amyloidosis 19Lymphoma, Mantle-Cell 18Ovarian Neoplasms 17Carcinoma, Non-Small-Cell Lung 17Waldenstrom Macroglobulinemia 16Lung Neoplasms 16Lymphoma, Follicular 15Lymphoproliferative Disorders 14Leukemia, Myelogenous, Chronic, BCR-ABL Positive 14Blood Protein Disorders 14

Interventions

Dexamethasone 2ricolinostat 1pomalidomide 1daratumumab 1Lenalidomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Disease × Plasma cell × Clear all
NCT07075185 2026-04-24

inMMyCAR

Kelonia Therapeutics, Inc.

Phase 1 Recruiting
70 enrolled
LymphoidPlasma cell

Blood Protein Disorders, Disease, Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Vascular Diseases, Hemostatic Disorders

NCT05641324 2024-02-12

A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2)

Anaveon AG

Phase 1 Terminated
4 enrolled
Plasma cell

Disease, Hematologic Diseases, Multiple Myeloma, Neoplasms, Recurrence

NCT02189343 2019-11-21

Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed-and-Refractory Multiple Myeloma

Celgene

Phase 1 Completed
16 enrolled
Plasma cell

Disease, Multiple Myeloma, Recurrence, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡